SG Americas Securities LLC Purchases 13,945 Shares of Guardian Pharmacy Services, Inc. $GRDN

SG Americas Securities LLC boosted its position in Guardian Pharmacy Services, Inc. (NYSE:GRDN) by 274.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 19,017 shares of the company’s stock after purchasing an additional 13,945 shares during the period. SG Americas Securities LLC’s holdings in Guardian Pharmacy Services were worth $572,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its position in Guardian Pharmacy Services by 26.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after purchasing an additional 345 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in Guardian Pharmacy Services in the 3rd quarter worth about $30,000. Parkside Financial Bank & Trust grew its position in Guardian Pharmacy Services by 70.5% in the 3rd quarter. Parkside Financial Bank & Trust now owns 3,248 shares of the company’s stock worth $85,000 after purchasing an additional 1,343 shares in the last quarter. JPMorgan Chase & Co. grew its position in Guardian Pharmacy Services by 31.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,899 shares of the company’s stock worth $207,000 after purchasing an additional 1,872 shares in the last quarter. Finally, Marshall Wace LLP grew its position in Guardian Pharmacy Services by 13.9% in the 2nd quarter. Marshall Wace LLP now owns 15,442 shares of the company’s stock worth $329,000 after purchasing an additional 1,883 shares in the last quarter.

Analyst Upgrades and Downgrades

GRDN has been the subject of a number of recent analyst reports. Oppenheimer upped their price objective on shares of Guardian Pharmacy Services from $35.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, March 12th. Zacks Research upgraded shares of Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 18th. Raymond James Financial reiterated an “outperform” rating and issued a $40.00 target price on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research note on Friday, March 27th. Finally, Jefferies Financial Group started coverage on shares of Guardian Pharmacy Services in a research note on Monday, March 30th. They issued a “buy” rating and a $44.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Guardian Pharmacy Services currently has an average rating of “Buy” and an average target price of $39.20.

Guardian Pharmacy Services Stock Up 0.1%

GRDN opened at $39.19 on Monday. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of 50.90 and a beta of 0.47. Guardian Pharmacy Services, Inc. has a twelve month low of $19.17 and a twelve month high of $41.36. The company’s 50-day moving average price is $34.65 and its two-hundred day moving average price is $30.76.

Guardian Pharmacy Services (NYSE:GRDN) last released its earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.10. The firm had revenue of $397.62 million for the quarter, compared to analysts’ expectations of $390.04 million. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. Guardian Pharmacy Services’s revenue was up 17.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current year.

Insider Activity at Guardian Pharmacy Services

In related news, major shareholder Equity Fund L.P. Cardinal sold 275,728 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $8,183,607.04. Following the sale, the insider directly owned 345,123 shares in the company, valued at approximately $10,243,250.64. This represents a 44.41% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Fred Burke sold 671,432 shares of the company’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $29.68, for a total transaction of $19,928,101.76. Following the sale, the insider owned 840,413 shares in the company, valued at $24,943,457.84. The trade was a 44.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 9,726,405 shares of company stock worth $288,679,700 in the last ninety days. Insiders own 32.96% of the company’s stock.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.